Search results for "Steatosi"

showing 10 items of 261 documents

Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma

2016

Obesity increases hepatocellular carcinoma (HCC) risks via unknown mediators. We report that hepatic unconventional prefoldin RPB5 interactor (URI) couples nutrient surpluses to inflammation and non-alcoholic steatohepatitis (NASH), a common cause of HCC. URI-induced DNA damage in hepatocytes triggers inflammation via T helper 17 (Th17) lymphocytes and interleukin 17A (IL-17A). This induces white adipose tissue neutrophil infiltration mediating insulin resistance (IR) and fatty acid release, stored in liver as triglycerides, causing NASH. NASH and subsequently HCC are prevented by pharmacological suppression of Th17 cell differentiation, IL-17A blocking antibodies, and genetic ablation of t…

Male0301 basic medicineCancer ResearchCarcinoma HepatocellularInflammationWhite adipose tissueDiet High-FatMice03 medical and health sciencesNon-alcoholic Fatty Liver DiseasemedicineAnimalsHumansUnconventional prefoldin RPB5 interactorbiologyInterleukin-17Liver NeoplasmsFatty liverIntracellular Signaling Peptides and ProteinsCell Biologymedicine.diseasedigestive system diseasesGene Expression Regulation NeoplasticRepressor Proteins030104 developmental biologyNeutrophil InfiltrationOncologyHepatocellular carcinomaImmunologybiology.proteinTh17 CellsInterleukin 17SteatosisSteatohepatitismedicine.symptomDNA DamageCancer Cell
researchProduct

Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up.

2016

Abetalipoproteinemia (ABL; OMIM 200100) is a rare autosomal recessive disease that affects the absorption of dietary fats and fat soluble vitamins. Here, we describe the clinical and genetic characteristics of three patients with ABL. Two patients (patients 1 and 2) who were carriers of the c.398-399delAA mutation (previously known mutation) had developmental delay and hepatic steatosis developed at the age of five in patient 1. Patient 3 was the carrier of a novel mutation (g.10886-10902delAAGgtaagtttgtgttg in intron 3 and c.506A>T exon 5) in microsomal triglyceride transfer protein (MTP) gene and had hepatic steatosis.

Male0301 basic medicineHeterozygotemedicine.medical_specialtySettore MED/09 - Medicina InternaTurkeyDevelopmental delayDevelopmental DisabilitiesTurkish030204 cardiovascular system & hematologyHepatic steatosimedicine.disease_causeMicrosomal triglyceride transfer protein03 medical and health sciencesExon0302 clinical medicineInternal medicineHumansMedicineGeneGenetic Association StudiesGeneticsMutationABLbiologyAbetalipoproteinemiaDevelopmental delayHepatic steatosisMicrosomal triglyceride transfer proteinTurkishbusiness.industryIntronGastroenterologyInfantAbetalipoproteinemiaMicrosomal triglyceride transfer proteinmedicine.diseaseIntronsAbetalipoproteinemiaFatty Liver030104 developmental biologyEndocrinologyMutationbiology.proteinFemaleSteatosisCarrier ProteinsbusinessFollow-Up Studies
researchProduct

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to devel…

2016

Disruption of the vectorial bile acid transport in the liver is a key feature of cholestatic drugs, although many causal and mechanistic aspects are still unknown. The aim of the present study was to explore if cholestatic drugs can repress or induce the expression of hepatic transporters. To this end, sandwich-cultured rat hepatocytes were treated with cholestatic and non-cholestatic (steatotic, non-hepatotoxic, etc.) drugs and the mRNA expression of 10 uptake and efflux biliary transporters was measured. Results evidenced that all cholestatic drugs cause extensive alterations in the mRNA expression of most biliary transporters. Surprisingly, nearly all steatotic drugs also affected the ex…

Male0301 basic medicinePathologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug Evaluation PreclinicalOrganic Anion Transporters Sodium-IndependentPharmacologyBiologyToxicology030226 pharmacology & pharmacyRats Sprague-Dawley03 medical and health sciences0302 clinical medicineCholestasisPredictive Value of TestsIn vivomedicineAnimalsBileRNA MessengerCells CulturedCholestasisMultidrug resistance-associated protein 2Fatty liverTransporterGeneral Medicinemedicine.diseaseRatsFatty Liver030104 developmental biologyTetracyclinesHepatocytesBiomarker (medicine)EffluxSteatosisCarrier ProteinsBiomarkersToxicology Letters
researchProduct

Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet

2016

Previous studies suggested that endogenous glucagon-like peptide 2 (GLP-2) is dispensable for the regulation of glucose homeostasis under normal conditions, while it can play a beneficial role in obesity conditions. The purpose of the present study was to investigate whether chronic treatment with Gly2-GLP-2, a stable analogue of GLP-2, can have an impact on glycaemic and lipid control in mice fed a high-fat diet (HFD), an animal model of human obesity and insulin resistance. HFD mice were treated once a day with Gly2-GLP-2 for 4 weeks. Body weight, food intake, fasting glucose, intraperitoneal glucose tolerance, insulin-induced glucose clearance, glucose-stimulated insulin secretion, β-cel…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDrug Evaluation PreclinicalMicrovesicular SteatosisCarbohydrate metabolismDiet High-FatSettore BIO/09 - FisiologiaRandom Allocation03 medical and health sciencesEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusGlucagon-Like Peptide 2medicineAnimalsGlucose homeostasisObesityPancreasPancreatic islets.Glucose Metabolism Disordersbusiness.industrydigestive oral and skin physiologyInsulin resistancemedicine.diseaseGlucagon-like peptide-2LipidsObesityMice Inbred C57BL030104 developmental biologyEndocrinologyLiverPeptidesbusinessGLP-2Dyslipidemia
researchProduct

Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabol…

2020

Objective: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver morbidity. This condition often is accompanied by obesity, diabetes, and metabolic syndrome (MetS). The aim of this study was to evaluate the connection between lifestyle factors and NAFLD in individuals with MetS. Methods: A cross-sectional study with 328 participants (55-75 y of age) diagnosed with MetS participating in the PREDIMED-Plus trial was conducted. NAFLD status was evaluated using the non-invasive hepatic steatosis index (HSI). Sociodemographic, clinical, and dietary data were collected. Adherence to the Mediterranean diet (mainly assessed by the consumption of olive oil, nuts, legumes…

Male0301 basic medicinemedicine.medical_specialtyMediterranean dietEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiet MediterraneanDiet SurveysSeverity of Illness Index03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsSurveys and QuestionnairesNAFLDInternal medicineDiabetes mellitusmedicineHumansObesityExerciseLife StyleAgedRandomized Controlled Trials as TopicNutritionMetabolic SyndromeInflammation2. Zero hunger030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryFatty liverMiddle Agedmedicine.diseaseObesityConfidence interval3. Good healthCross-Sectional StudiesSpainRelative riskLinear ModelsPatient ComplianceFemaleSteatosisMetabolic syndromebusinessNutrition
researchProduct

Impact of diet-induced obesity on the mouse brain phosphoproteome

2018

Obesity is closely associated to several diseases such as type 2 diabetes, cardiovascular disease, hepatic steatosis, airway disease, neurodegeneration, biliary diseases and certain cancers. It is, therefore, of importance to assess the role of nutrition in disease prevention as well as its effect in the course of such pathologies. In the present study, we addressed the impact of the exposure to different obesogenic diets in the mice brains phosphoproteome. To analyze if the obesity could be able to modify the protein pattern expression of brain neurons, obesity was induced in two different groups of mice. One group of mice was fed with hyperglycemic diet (HGD) and the other one was fed wit…

Male0301 basic medicinemedicine.medical_specialtyPhosphoproteomicsEndocrinology Diabetes and MetabolismClinical BiochemistryHyperglycemic dietType 2 diabetesDiseaseBiologyDiet High-FatBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsProtein phosphorylationObesityPhosphorylationMolecular BiologyGSK3BNutritionNeuronal impairmentNutrition and DieteticsNeurodegenerationta1182BrainObesity; Nutrition; High-fat diet; Hyperglycemic diet; Neuronal impairment; PhosphoproteomicsPhosphoproteinsmedicine.diseaseObesityMice Inbred C57BLHigh-fat dietGene Ontology030104 developmental biologyEndocrinologyHyperglycemiaPhosphorylationCalcium ChannelsSteatosis030217 neurology & neurosurgeryThe Journal of Nutritional Biochemistry
researchProduct

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

2018

Background & Aims: Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic steatosis, but it has not been evaluated in alcoholic liver disease. Therefore, we aimed to validate CAP for the assessment of biopsy-verified alcoholic steatosis and to study the effect of alcohol detoxification on CAP. Methods: This was a cross-sectional biopsy-controlled diagnostic study in four European liver centres. Consecutive alcohol-overusing patients underwent concomitant CAP, regular ultrasound, and liver biopsy. In addition, we measured CAP before and after admission for detoxification in a separate single-centre cohort. Results: A total of 562 patients were included in the s…

MaleAlcoholic liver diseasemedicine.medical_treatmentBiopsyGastroenterologyCohort StudiesSensitivity0302 clinical medicineInterquartile rangeRisk FactorsAlcohol detoxificationNon-invasiveSteatohepatitisUltrasonography2. Zero hungerMetabolic Syndromemedicine.diagnostic_testAlcohol AbstinenceFatty liverAlcohol detoxificationDiagnostic testMiddle Aged3. Good healthAlcoholismLiver030220 oncology & carcinogenesisLiver biopsyControlled attenuation parameterSpecificityElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleFatty Liver AlcoholicAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsFatty liverInternal medicinemedicineHumansFibroScanHepatologybusiness.industryAlcoholic liver diseasemedicine.diseaseCross-Sectional StudiesConcomitantSteatohepatitisSteatosisbusinessJournal of hepatology
researchProduct

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area

2018

Coffee drinking seems to have several beneficial effects on health outcomes. However, the effect on hepatic steatosis, depending on a high alcohol consumption (AFLD, alcoholic fatty liver disease) or on metabolic factors (non-alcoholic fatty liver disease, NAFLD), is still equivocal. Thus, we aimed to explore the potential association between coffee consumption and the presence and severity of hepatic steatosis in people with NAFLD or AFLD. In this cross-sectional study, coffee drinking was recorded using a semi-quantitative food frequency questionnaire, and categorized as yes vs. no and as 0, 1, 2, ≥3. The degree of fatty liver was assessed through a standardized ultrasound examination (sc…

MaleCross-sectional studyBlood PressureGastroenterologyBody Mass Indexchemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesPrevalencecaffeineAged 80 and overNutrition and DieteticsultrasoundMediterranean RegionFatty liverMiddle Aged3. Good healthItaly030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologyepidemiologyFemaleWaist CircumferenceCaffeinelcsh:Nutrition. Foods and food supplyFatty Liver AlcoholicAdultmedicine.medical_specialtyAlcohol Drinkingcoffeelcsh:TX341-641Article03 medical and health sciencesInternal medicinemedicineHumansfatty liver; coffee; caffeine; ultrasound; epidemiologyfatty liverAgedbusiness.industrycaffeine; coffee; epidemiology; fatty liver; ultrasoundOdds ratiomedicine.diseaseCross-Sectional StudiesLogistic ModelschemistryAlcoholic fatty liverSteatosisbusinessBody mass indexFood ScienceNutrients; Volume 10; Issue 1; Pages: 89
researchProduct

Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Mic…

2021

We have shown that prebiotic xylo-oligosaccharides (XOS) increased beneficial gut microbiota (GM) and prevented high fat diet-induced hepatic steatosis, but the mechanisms associated with these effects are not clear. We studied whether XOS affects adipose tissue inflammation and insulin signaling, and whether the GM and fecal metabolome explain associated patterns. XOS was supplemented or not with high (HFD) or low (LFD) fat diet for 12 weeks in male Wistar rats (n = 10/group). Previously analyzed GM and fecal metabolites were biclustered to reduce data dimensionality and identify interpretable groups of co-occurring genera and metabolites. Based on our findings, biclustering provides a use…

MaleDOWN-REGULATIONsuolistomikrobistoHealth Toxicology and Mutagenesismedicine.medical_treatmentOligosaccharidesPROTEINAdipose tissuelcsh:MedicineGut florabiclusteringGLUCOSE0302 clinical medicineAMINO-ACIDSxylo-oligosaccharidesaineenvaihduntametabolites2. Zero hungerINSULIN-RESISTANCE0303 health sciencesmicroRNAhigh fat diet1184 Genetics developmental biology physiology3142 Public health care science environmental and occupational health3. Good healthCHAIN FATTY-ACIDSAdipose TissueLiverB-CELLSOBESITY1181 Ecology evolutionary biology030211 gastroenterology & hepatologymedicine.symptommedicine.medical_specialtyInflammationBiologyDiet High-FatArticle03 medical and health sciencesMetabolomicsprebiootitLIVER-DISEASEInternal medicineMetabolomemedicineAnimalsbiochemistryRats Wistar1172 Environmental sciences030304 developmental biologyInflammationgut microbiotaPrebioticlcsh:RPublic Health Environmental and Occupational Healthnon-alcoholic fatty liver diseaseACETYL-COA CARBOXYLASEksylo-oligosakkariditbiology.organism_classificationmedicine.diseaserotta (laji)Fatty LiverratsInsulin receptorEndocrinologyei-alkoholiperäinen rasvamaksasairaus3121 General medicine internal medicine and other clinical medicinebiology.proteinaineenvaihduntatuotteetkoe-eläinmallitSteatosismikro-RNAInternational Journal of Environmental Research and Public Health
researchProduct